SciSparc unit NeuroThera pursues FDA orphan drug designation for adult Tourette
NeuroThera Labs, a SciSparc subsidiary, is pursuing FDA orphan drug designation for an adult Tourette Syndrome treatment and has engaged RK Strategies for government and public affairs support.
(TheNewswire)This strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public—health importance of advancing new treatment options for adult Tourette SyndromeTEL AVIV, Israel — TheNewswire - Sept…